aPODD - accelerating Pardiatric Oncology Drug Development Logo

Target Diseases


Cancers affecting children are generally different from those affecting adults. Some forms of blood cancers (e.g. leukaemia, lymphomas) are common, but some solid tumours either do not occur in adults, or are extremely rare (e.g. neuroblastoma, rhabdomyosarcoma).


Drugs that were originally developed for adult cancers continue to be used to treat children, despite the poor results. Currently there is little incentive for companies to develop drugs specifically for children or to systematically evaluate adult drugs in childhood cancers, due to the high costs and potentially low return on investment.



Type of Cancer


Solid tumour

Cancer not originating in the blood.  It is a solid tumour mass, which sometimes can be surgically removed, but can spread in more advanced cases


Cancer of the blood

CNS (Central Nervous System) tumours

Tumour originating in the brain or spinal chord


Tumour of the peripheral nervous system originating outside the brain and the spinal cord.  Typically occur in the abdomen, neck and limbs

Gonadal GCT (Germ Cell Tumour)


Cancer originating in the ovaries or testes

Wilm’s Tumour

Kidney tumour

Thyroid Carcinoma

Cancer of the thyroid gland


Bone cancer

Rhabdomyosarcoma and Ewings Sarcoma

Aggressive cancers of the connective tissue, typically originating in the abdomen


Skin cancer


Cancer of the eye


Liver cancer


News All News »

More ambitious collaborative models are needed - Open Letter
We often hear from childhood cancer charities calls for deeper and wider collaborations among key stakeholders. I fully agree that collaborations are beneficial but I do feel that we must further...
read more

Childhood Cancer Facts

Drug Development for Childhood Cancers

Childhood cancers are different and new drugs against these diseases are not specifically developed. More and more targeted drugs are being developed for adults but these new drugs are not systematically evaluated in children. Any new anti-cancer compound will be fully evaluated in children many years after its first approval. Children are largely unaffected by the recent advances of cancer drug discovery

read more